Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Oh, thanks Maivoce, I think I need to re -read the article to get my timings correct.
Will this study not already be finished given that the REC approval was given in Apr 2023 ?
Wonder why Scancell didn't RNS this ?
Will the info , when completed, be widely shared, or just with Scancell??
If a pharma was interested in this, would it be logical for them to wait ( if they can access the results) before making an offer for this mAB ?
Thanks Burble , thought that would be the case
have you Listened to Seth's recent Presentation which I have posted before , mentions this is an excellent presentation
https://www.youtube.com/watch?v=-kF_G22FANE
1.6 mins in
Epitope small cell lung cancer with Scib
2. 8 mins in positive differences and advantages of the Scancell Melanoma vaccine over personalised and off the self offerings . The concern of the NHS hospitals and logistics of treating patients for 2 years ( storage etc)
3. mentions the Glymab Platform .
Posted yesterday :
On Linked in post from Scancells research scientist Bubacarr G Kaira :
Glycans are important and can be considered as the icing on the cake.
And in the context of glycan mediated disease, understanding the function of glycans on proteins is key. Additionally, glycans are aberrantly overexpressed on cancer cells and targeting these glycans as strategy to kill cancer cells is essential and Scancell Ltd is a leader in producing anti-glycan antibodies (#GlyMab) against cancer cells.
Fortunately, some very prominent conferences like ISABS are taking place in Croatia, so I do not have to travel far... Recording of my yesterday's plenary lecture "Glycan biomarkers for personalized preventive healthcare" at the 13th Congress of the International Society for Applied Biological Sciences is available here.
With the following presentation , which listen to understand just how important Glycol are
From professor Gordon Lauc
Prof Gordan Lauc: Glycan biomarkers for personalized preventive healthcare
https://www.youtube.com/watch?v=_LrS9my_ioQ
Burble, yes they are using biopsy samples from patients...
"The main aim of this study is to assess the sugar-lipid distribution pattern on the cancer cells in SCLC cases in order to find which patients with SCLC might benefit from antibody therapy. We need to collect lung biopsy samples from patients being investigated for possible lung cancer so that we can look at any cancer cells in the laboratory and analyse them for the presence and distribution of the sugar-lipid."
That 79 pence price target was when there was a possibility of a deal following on from the first SCIB1 trial.
Of course, there were far fewer shares in issue at that time. However, it will be interesting to see if they specify a new price target and what that target will be.
RR, If so ..........shows you how correct they were.....we're still waiting. IMO
I remember those days as well!
From memory they had a target price of 79p.
Perhaps they will reinstate that now they are back.
Hi C7, great to see you are posting !
Yes , I believe you are correct, Panmure were acting for us previously.
I suspect that Stifel cut their relationship person…..
https://www.fnlondon.com/articles/stifel-cuts-up-to-15-london-jobs-amid-uk-ipo-slump-1bc609f3
Makes sense to go back to Panmure.
Started: Bermudashorts, 20 Jun 2024 14:44
Last post: MattRempit, 20 Jun 2024 17:45
A terrible, cruel disease. Condolences to his family and friends all.
Yes, sad news indeed RIP John.
I remember one AGM when someone asked a question about the SP. He dismissed it with distain saying “the BOD have absolutely zero control over the SP. Next?”
That stuck with me and over the years has stopped me getting too worked up about the SP.
Top posts from Ray & RW
Sad news indeed R.I.P.
Whereas the conspiracy theorists and bad mouthers who speculated maliciously on the reasons for his departure will.
Life is very unfair. R.I.P. John Chiplin.
Started: magnetmagnetism, 20 Jun 2024 13:16
Last post: magnetmagnetism, 20 Jun 2024 13:16
I've listened a number of times to the last 1.5 minutes of the interview.
I've flip-floped a number of times on what she's actually thinking / saying.
Started: Cleanerworld, 7 Dec 2022 16:32
Last post: TorquayFan, 19 Jun 2024 16:15
Ripley at 4.15 we haven't nudged up let alone made 11p, so that was a waste of time. A bit of chat has always been accepted here, it's the mischief that's the pain.
Ciaskin and Violin, yes the Govt seems to be besotted with Moderna but I suggest that's as a result of the perceived success of their covid vaccine rather than being due to favouritism because of past connections to Sunak. Of course a dose of cynicism is helpful but atm cynicism seems to cloud most comment which is unhealthy in itself.
I see the share price has improved a little might hit 11p today .
I wonder how much the company had to pay this site for the ramp vidio advert post , the vidio advert on the whole site for a week now.
A lot of time-wasting type posts appearing again .
My broker has these down 3% today , and only downward direction all day on there chart .
The spread was more then the rise at 9am.
I see admin have made a post at 9am !!
"Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here."
Scinv_temp this appears to be only share you post on of late .
Just had a look and see in 2023 no comments by you until late October .
Started: JohnnyB1, 18 Jun 2024 22:07
Last post: violindog, 19 Jun 2024 11:31
Ciaskin, agree totally. The government has sold the UK future to Moderna and most likely your NHS health data as well . Is there a link between this and Rishi's Moderna investment...surprised if not !!!
I wouldn't read too much into that. Fact is, HM Gov are thick as thieves with Moderna, the same Moderna that Rishi's previous hedge fund owns squillions of shares in, - and the same hedge fund that Rishi still has shares. That's his pension sorted.
There is probably nothing in it and it is a bit above my pay grade to be honest. I am just wondering whether there is a possibility that the UK Government might help to support and accelerate Scancell’s Modify or Scope trials.
The reason I ask is because I have noticed that Maria Kuofali. Programme Director, UK Vaccine Innovation Pathway has liked a couple of Scancell’s posts on Linked in recently (Including Scancell’s post 2 weeks ago confirming MHRA approval to add an expansion cohort to the ModiFy trial).
This is a link to Maria Koufali and the Vaccine Innovation Pathway:-
https://www.nihr.ac.uk/blog/how-the-vaccine-innovation-pathway-is-advancing-vaccine-clinical-trials/35506
This is a link to a message about the “Vaccine Innovation Fund, a pivotal component of the Moderna Strategic Partnership with the UK” she sent to her colleagues earlier this year:-
https://www.nhsresearchscotland.org.uk/uploads/tinymce/UK%20Vaccine%20Innovation%20Fund%20_%2014%2002%2024.pdf
Last post: violindog, 19 Jun 2024 11:09
Thanks Drac , just a question of when to anticipate the lowest level to place a deal. A penny either side of 10p doesn't sound much , especially when we receive our 50p + bid 🤞... but on this final deal to lower my average...I want a "psychological win" if you understand my reasoning.
Violin, spot on there. Old saying It's a Ill wind that doesn't blow some good. Glad that you can make use of the lower SP.
BOL.
The seller has been around for months and it’s most likely Calculus. They provided great support in the early days.
Drac.... changed my thinking completely. I have come to the conclusion retail investors in Sclp will not be our saviours. A knock out bid is the answer which I'm incredibly confident will occur.... and it will meet or more likely exceed my 50p target.
My only concern re the recent frequent seller is that I am trying to lower my average as much as possible with my next purchase. If the SP drops alittle due to the sellers action then I will make my purchase .
Sure Is Violin,
What's your take on It. SP definitely going no here as can be seen by all. IMO
Started: Bermudashorts, 18 Jun 2024 10:28
Last post: CHELSEA7, 19 Jun 2024 08:34
Sums up why trolls post.
Shame really good posts from Konar and Bermudashorts, to name just two.
Frankly I couldn’t see anything on this board for the stream of disruptive posts. It is like ADVFN used to be…..
Morning TF, guess you are right, the replies Scin_v provoked has led to some awesome reposts as we read yesterday.
I posted last week just an article on how far we are behind other countries in cancer care and survival, ignoring the noise we are subjected to.
I only watch the news on Sky for about ten minutes in the morning now, and they say we are 25 years behind other countries, particularly Denmark and Norway in Cancer treatments and care. Mind boggling!!!
I didn’t agree with ScinV’s point of view and it did seem like he was goading Berm.
However, I am sure Berm is well able to look after himself but worse behaviour is with the self righteous p**ck who would dictate to us what we can and cannot see on this BB.
The fragile ego that had ScinV’s posts deleted is a bigger bully than ScinV and probably exerts coercive control on somebody in his real life circle and is without doubt a pathetic and weak individual.
Ray I didn't say Scinv did, 'educate we fools'. But some of the ensuing replies to him were useful.
Started: Cleanerworld, 18 Jun 2024 16:41
Last post: Cleanerworld, 18 Jun 2024 16:41
Bubacarr G Kaira said on linked in
“Glycans are important and can be considered as the icing on the cake.
And in the context of glycan mediated disease, understanding the function of glycans on proteins is key. Additionally, glycans are aberrantly overexpressed on cancer cells and targeting these glycans as strategy to kill cancer cells is essential and Scancell Ltd is a leader in producing anti-glycan antibodies (#GlyMab) against cancer cells.”
He shared this presentation Prof Gordan Lauc , Professor of Molecular Biology & Founder and CEO of Genos, the leading provider of high-throughput glycomics
Topic
Glycan biomarkers for personalized preventive healthcare
Plenary lecture at 13th ISABS conference. Split, Croatia, June 17, 2024
link well worth listening to
https://www.youtube.com/watch?v=_LrS9my_ioQ
Started: Bermudashorts, 17 Jun 2024 17:49
Last post: Scinv_temp, 18 Jun 2024 11:41
(This IS goodbye IF my previous comment remains in place)
I see you had ny comment on how it actually works deleted. A behaviour all too familiar from people who don't care about facts. Bermuda is either not familiar with how this works (therefore he mislead you about being an expert) or he is an expert and has an agenda. You decide.
Read below
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183261/
And the general guidelines from NCI (note the .gov in the link before you say anything silly)
https://ctep.cancer.gov/protocoldevelopment/docs/quickrcst.doc
This is what I wrote previously
Scinv_temp
Posts: 1,207
Price: 9.65
No Opinion
RE: Morning10 Jun 2024 08:52
4.5. Frequency of tumour re-evaluation
Frequency of tumour re-evaluation while on treatment should be protocol specific and adapted to the type and sche- dule of treatment. However, in the context of phase II studies where the beneficial effect of therapy is not known, follow-up every 6–8 weeks (timed to coincide with the end of a cycle) is reasonable.
[...]
Recist 1.1 guidelines
https://project.eortc.org/recist/wp-content/uploads/sites/4/2015/03/RECISTGuidelines.pdf
If you read the paper that Bermuda posted they report from the phase 1 part, not the phase 2. In addition, ORR is not in the primary or the secondary outcome of the study but in the "other outcomes" which are exploratory.
Isn't funny that Bermuda only lets you reply to me but he never does himself and also refuses to admit that he has nothing to do with biomedical sciences and that he is in fact a finance person?
Ruck, couldn"t agree more. I said exactly the same thing in a post to Scin_v, which he responded to last week.
Another respected poster here. posted a cryptic message here last week as to his true identity, not sure if you saw it, but it called him out as being our dear old friend Knowlesi.
Since being out of here I can read into any negative comments without wearing rose tinted glasses, but I must say his posts IMHO are designed in their repetitive and innaccuricies just to be disruptive.
As you always used to say, just ignore them if you feel the same. Hope you are doing well buddy, can"t believe we are all 12 years older than we were when we invested and posted here to begin with!!!!
ATB.......C7
Scinv,
I do give consideration to every post and viewpoint - yours being no exception.
Whilst you may well have a point (I don't understand enough about trial protocols to make a judgement) what I DO know is that Bermuda would not deliberately be dishonest. If he had someone wrong who would readily admit it.
So when you call into question the honesty and integrity of one of the most respected posters you just reveal yourself as a bullying egotist.
Goodbye?…I doubt that is truthful!…but I live in hope!
Last post: Rob23460, 18 Jun 2024 11:12
DeAar....... I agree with the sentiment but the post's by Sciv seemed completely off the wall at the times. The content and accusations contained in some were completely uncalled for. The BB is a medium where debate from both sides should be heard but for whatever reason Sciv who from memory appeared from nowhere seems/ed intent on provoking an argument wether the facts were true or false.
Thank you Berm for a yet again in my opinion a well informed post regarding Evaxion
Started: Bermudashorts, 18 Jun 2024 11:03
Last post: Bermudashorts, 18 Jun 2024 11:03
Moving on and much more important, a big round of applause for Merck who have today announced FDA approval of Keytruda in combination with chemo for advanced endometrial cancer. This is the 40th indication for which Keytruda has secured FDA approval - an incredible achievement and who knows how many lives have been saved/extended thanks to these PD-1 inhibitors.
https://www.businesswire.com/news/home/20240617180729/en/FDA-Approves-Merck%E2%80%99s-KEYTRUDA%C2%AE-pembrolizumab-Plus-Carboplatin-and-Paclitaxel-as-Treatment-for-Adult-Patients-With-Primary-Advanced-or-Recurrent-Endometrial-Carcinoma?utm_campaign=shareaholic&utm_medium=twitter&utm_source=socialnetwork
Started: Cleanerworld, 17 Jun 2024 12:42
Last post: Cleanerworld, 17 Jun 2024 12:42
From Marcus on the other board exciting
BiotechTV on LinkedIn: 🗣️ 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐦𝐞𝐧𝐭: BiotechTV is excited to welcome Amy Brown as…
BiotechTV coverage of the uk
The pitch at the end was really good giving email address of where to send stories
Amy@biotechTV.com
Started: TorquayFan, 17 Jun 2024 11:43
Last post: TorquayFan, 17 Jun 2024 11:51
And looking back a little, thanks Johnny - Scancell are making good progress with SC134 and this statement on Modi2 - "with the aim of initiating a Phase 1 clinical study in cancer patients in 2024". Now in reality that may not happen quite on cue but it's a very exciting prospect ! ATB
Some useful posts today. Thanks EE and Cleaner, I watched Sath again at 6.5 and 8 mins. C11 Good point re. Avidimab - there is a potential for big money with the Glycans too.
If the Immunobody data comes through well, (and Team Scancell sound confident), I'll stick my neck out and say that platform alone should fetch £3 billion upwards - I won't be debating that figure, it's just my own view.
Nice day all.
Started: Cleanerworld, 14 Jun 2024 13:18
Last post: Cleanerworld, 17 Jun 2024 08:31
Yes EE , have you also listened to the Scancell Holdings PLC presentation by Sath Nirmalananthan, CFOat the 10th Annual Oncology Innovation Forum SACHS
https://www.youtube.com/watch?v=-kF_G22FANE
this is an excellent presentation
Epitope small cell lung cancer with Scib
Listen 6,5 mins in
Listen 8 min really exciting and positive
in a competitive advantage SCIB 1 advantages and positioning ourselves to be difference
re Moderna and Biotech to personalised vaccine
Uk feedback NHS hospitals form storing personalised vaccine and being able to logisticaly treat patients for 2 years
The global cancer monoclonal antibody market size $42B in 2021. Market expected to reach $57B by 2028 (IMARC Report 2023).
It’s reasonable to think that there are discussions ongoing re the out-licence of AvidiMab, given that in theory, it can be applied to any antibody.
That wouldn’t come cheap and might fill a few self-fund tins.
Everything is pointing to a major corporate event in Q4 or the first half of 2025. Are they going to self fund the future (with eg a NASDAQ listing and a raise and/or merger) or is someone going to take out the whole company first? We will find out in the coming months.
The focus is clearly on the Scope and Modify trials. However, something else caught my attention on the pipeline slide 3 minutes 20 seconds into the video:-
https://www.proactiveinvestors.co.uk/companies/news/1049866/scancell-holdings-promising-cancer-vaccine-developments-for-advanced-melanoma-one2one-forum-1049866.html
If you look at the arrows for Modi 2 and SC134 (The antibody Scancell want to bring into the clinic themselves), these are both very deep into the Pre-clinical section and almost on the cusp of the Phase 1 section. These appear to indicate that they are very close to bringing into the clinic.
Modi 2: The RNS 7 November’22 states “This agreement will allow Scancell to formulate and manufacture Modi-2, with the aim of initiating a Phase 1 clinical study in cancer patients in 2024”. It is also worth noting that Scancell are doing a presentation on Modi 2 at the Immuno-Oncology summit on 7 August’24:-
https://www.immuno-oncologysummit.com/cancer-vaccines?utm_source=linkedin&utm_medium=social&utm_campaign=vjm_final_track_agenda_20240423
Started: CHELSEA7, 17 Jun 2024 07:00
Last post: CHELSEA7, 17 Jun 2024 07:00
Https://news.cancerresearchuk.org/2024/02/27/how-does-cancer-treatment-in-the-uk-measure-up/
Wonder who put the Great in Britain?
What a national disgrace
Started: BiotechBilly, 16 Jun 2024 23:01
Last post: WeTookPelham, 16 Jun 2024 23:12
I have wondered if the 7 month deadline RE the major pharma evaluation will start causing some urgency to look into Scancell as a whole. Surely a big pharma who could comfortably afford to buy out the lot would be thinking they would be getting the jump on their competitors and more importantly getting the multiple platforms. We've often said the pipeline exceeds that of much bigger bios.
It is certainly the case that Scancell could be the possibility of a future takeover. An indication of this would be when there is no particular reason for a rising share price. This could mean that the predator is buying up cheap stock.
Started: bobbust, 15 Jun 2024 17:52
Last post: chester18, 16 Jun 2024 13:16
Hi bobbust
That was a very positive and direct post.
Scancell are definitely on the way towards upsetting the apple cart. We could become a disruptive force in an otherwise well ordered and profitable space for some very large biotechs.
Even more important is the improvements Scancell could bring to a number of cancer settings. The sooner the better, so more lives can be improved or even saved.
I will be so happy once the data is released and it’s positive enough to start moving the share price above 20p. Once we move passed that figure with momentum we will certainly on the way towards your £1 prediction.
Nirmalananthan, CFO
at the 10th Annual Oncology Innovation Forum
https://www.youtube.com/watch?v=-kF_G22FANE
At the investor event in London
Https://www.proactiveinvestors.co.uk/companies/news/1049866/scancell-holdings-promising-cancer-vaccine-developments-for-advanced-melanoma-one2one-forum-1049866.html
Scancell Holdings PLC presentation by Sath Nirmalananthan, CFO
I agree with you
Find the presentation given by Sath in USA pre ASCO opening
And a few days before in London
In early testing we have bettered CPI as a mono therapy.
Over 60% are alive after 5 years.
CPI normal only work on 50% and only 20 are disease free.
In combination we early results are showing an increase from 50% to 85% and one disease free after only a few weeks.
And SCIB1 can be addable to other cancers.
It's better than a CPI and has limited side effects.
Once the full data is out this will not stop at £1
Started: nomlungu, 15 Jun 2024 22:07
Last post: nomlungu, 15 Jun 2024 22:07
Eric Topol interviews Charlie Swanton
https://www.youtube.com/watch?v=NG3K8mvcrqI
Some will find the link interesting
Last post: chester18, 15 Jun 2024 21:32
I put Scinv into the filter green bin and missed most of the post but seeing the post by DeAar I decided to read what was being said.
I just want to point out that when Lindy mentioned 27 patients immunised I’m sure that was in reference to the SCOPE trial as a whole. SCIB1 plus iSCIB+.
Let’s not post under the subject of Bermuda.
We all know Scinv is a joke and we can now move on.
Started: WeTookPelham, 13 Jun 2024 20:34
Last post: ratcliffewriter, 15 Jun 2024 17:50
'The truth is you are absolutely DISGUSTING.'
Not true.
You want to see me when I'm drunk.
'The truth is you are absolutely DISGUSTING.'
Not true.
You want to see me when I'm drunk.
Keep it up guys, after all Bermuda agrees 100% with you. He might even one up you with a nice prose.
He’s had a scinv-ful obviously!
*would not be able to afford
Started: DeAar, 14 Jun 2024 18:41
Last post: Scinv_temp, 15 Jun 2024 17:39
Keep it up guys, after all Bermuda agrees 100% with you. He might even one uo you with a nice prose.
Why havent you sold up SKinolewsi? Genuine question?
You clearly don't like the company, the CEO or it seems anything about it.
It would be better for your mental well being I think.
Hi GF, well the sellers relevance is only down to the low volume IMHO.
It is all relative.
C7.
Hope you are good.
Yes some unexpected trades have gone through and carefully managed. I
interesting statement on the other site. What I think is one of our old adversaries said “OK enough is enough. It is nearly time for my exit so I'm gonna let you fools resume the pumping. Goodbye”
Why exit after causing a few weeks of mayhem including accusations of CEO of lying.
Anyway have a good weekend. Football is off!
ATB
Yes De Aar, I didn"t want to mention it. Each day since the news the ask peaked and slowly fell during the day, there were 3 x 100k sells, 1 x 200k and todays 420k, all at 10p.
Maybe this seller has finished, but don"t take notice of me, I sold my last 150k last year when it fell to 9.1p!!!! 3 weeks later it bounced to 18p!!!!
Have a good weekend all.
Started: Rob23460, 14 Jun 2024 08:21
Last post: Cleanerworld, 14 Jun 2024 08:49
Yes your right LD did say that I was referring to the other interview she did recently in Oxford :
The words of Brad Loncar from BiotechTV when he visited companies at The Oxford Science Park (TOSP) last week. At TOSP, we have a long-established reputation for accommodating the best bioscience in Oxford, providing a thriving ecosystem for companies to succeed and scale.
One such advancing company is Scancell Ltd, whose scientists are making exciting progress in developing a cancer vaccine called SCIB1. Watch Brad’s interview with Lindy Durrant, Scancell CEO, in their labs at TOSP.
Hi cleaner,
Wasn’t the key statement from LD, T cells kill cancer and our products generate T cells.
Of course the checkpoint inhibitors reduce the cancer’s ability to resist the T cells.
Did Lindy say this or something similar ? please correct me
"the inhibitors help the vaccine and the vaccine helps the inhibitors "
from inacco other board
which one has failed
Scib1
or
Keytruda ( off patent v soon )
= no risk ...... they have to work together
“I think I’m there…….I think I’m nearly there” Says it all really.......perhaps we are finely getting into the end game and you either back that statement or you don't there is no in-between in my view now !!
Started: Dracula1, 14 Jun 2024 08:45
Last post: Dracula1, 14 Jun 2024 08:45
As of today Do posters believe that Modi and ScIBs are at?. Nice positive Interview. Nice to know SCLP Is on the market If /when the price Is right. IMO
Started: emptyend, 14 Jun 2024 08:07
Last post: emptyend, 14 Jun 2024 08:07
“I think I’m there…….I think I’m nearly there”